AREC
XLON
Market cap42mUSD
Nov 20, Last price
71.50GBP
1D
-5.92%
1Q
8.33%
IPO
-70.45%
Name
Arecor Therapeutics PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of specialized products (for diabetes and other ailments) and collaborate with pharmaceutical and biotechnology partners to refine and enhance existing therapeutic formulations. Its pipeline includes AT247, an exceptionally fast-acting insulin aimed at individuals with Type I and Type II diabetes, and AT278, a highly concentrated rapid-acting insulin formulation engineered to hasten insulin absorption following injection. Established in 2007, the company's main office is situated in Little Chesterford, United Kingdom.
Key people
Andrew Richards
Non-Executive Chairman of the Board · since 2021
Sarah Howell
Chief Executive Officer, Executive Director · since 2021
Helen Parris
Senior Vice President - Commercial and General Manager of Tetris Pharma Ltd · since 2024
Manjit Rahelu
Chief Business Officer · since 2023
David Ellam
Chief Financial Officer, Company Secretary · since 2024
Simon Ormiston
Non-Executive Director · since 2025
Alan Smith
Non-Executive Director · since 2021
Sam Fazeli
Independent Non-Executive Director · since 2021
Jeremy Morgan
Independent Non-Executive Director · since 2021
Independent Non-Executive Director · since 2021
Headquarters & legal address
Chesterford Research Park
Little Chesterford
Saffron Walden CB10 1XL
GB
Little Chesterford
Saffron Walden CB10 1XL
GB
Previous name
ARECOR THERAPEUTICS LIMITED
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑05 | 2018‑05 | 2017‑05 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||